Human antibody molecules for IL-13

Human antibody molecules for IL-13

  • CN 1,852,923 B
  • Filed: 07/15/2004
  • Issued: 05/27/2015
  • Est. Priority Date: 07/15/2003
  • Status: Active Grant
First Claim
Patent Images

1. for the specific binding members of the separation of huIL-13, comprise the antibody antigen-binding site be made up of people'"'"'s antibody VH domain and people'"'"'s antibody VL domain, wherein VH structural domain is made up of HCDR1, HCDR2 and HCDR3 and framework region, VL structural domain is made up of LCDR1, LCDR2 and LCDR3 and framework region, wherein this group CDR, namely HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are made up of following one group of CDR:

  • BAK502G9CDR group, be defined as wherein HCDR1 to be made up of the aminoacid sequence shown in SEQ ID NO;

    7, HCDR2 is made up of the aminoacid sequence shown in SEQ ID NO;

    8, HCDR3 is made up of the aminoacid sequence shown in SEQ ID NO;

    9, LCDR1 is made up of the aminoacid sequence shown in SEQ ID NO;

    10, LCDR2 is made up of the aminoacid sequence shown in SEQ ID NO;

    11, and LCDR3 is made up of the aminoacid sequence shown in SEQ ID NO;

    12Wherein said specific binding members is in conjunction with huIL-13 and rhesus monkey or macaque IL-13.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×